Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$344.1MCash, Jun 2026
26moCash Runway (est.)
Follow BBOT by emailGet an email when BBOT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BBOT, unsubscribe in one click. Privacy
📣 What BBOT Says Is Next
mid-2027 · “Data from BBO-11818 and BBO-10203 internal and standard-of-care combination cohorts in colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) expected in mid-2027.”
Company press release, Sep 8, 2026 · SEC filing
second half of 2026 · “Updated clinical data are expected in the second half of 2026 and internal combination studies are anticipated to open in 2026.”
Company press release, May 12, 2026 · SEC filing
second half of 2026 · “Updated clinical data are expected in the second half of 2026.”
Company press release, May 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
BBOT reported $344.1M in cash and short-term investments (as of Jun 30, 2026) and used about $40.5M/quarter in operations, an estimated runway of 25.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:25 · Moderate
Cash runway 26 months
ATM program on file since Sep 2026 +15
Shelf registration (S-3, Sep 2026) +10
Recent financing filings on SEC EDGAR:
Sep 1, 2026 · Shelf registration with ATM program, up to $200M · S-3
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BBOT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.